Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price target remains the same with $45.00. Mitchell ...
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points ...
Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus, or SLE. The company reported a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback